Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2014

View Archived Issues

Merz signs agreement with Brickell Biotech for novel retinoid therapy

China's regulatory authority approves phase II trials of F-351

Transcept Pharmaceuticals and Paratek Pharmaceuticals to merge

Pharmacodynamic effects of AZD-3241 revealed in PD patients

Osteogenesis improved in patients with hypophosphatasia

Johnson & Johnson completes divestiture of Ortho-Clinical Diagnostics

FOXO1 as a potential therapeutic target for diabetes demonstrated with AS-1842856

Vertex Pharmaceuticals discloses new ATR inhibitors for cancer

New CB2 receptor agonists patented by Roche

Allergan obtains FDA approval for Ozurdex and updates progress of key programs

Roche designs new SCD inhibitors for cancer

Agenus reports final results from phase II study of Prophage in newly diagnosed GBM

Rigel Pharmaceuticals divulges novel PKC inhibitors for ocular disorders

Researchers in the U.S. and China disclose new agents for cancer and other disorders

Genocea discloses 12-month follow-up data from phase I/IIa trial of HSV vaccine

Boston Strategics forms licensing deal with Eisai for E-6201

Scientists at Pierre Fabre design novel NMDA receptor antagonists

Synageva BioPharma reports topline data from phase III study of sebelipase alfa

Phase I first-in-human study begins for GLPG-1690

Insys Therapeutics receives FDA orphan drug designation for CBD

Genentech to acquire Seragon Pharmaceuticals

Oncoceutics presents preclinical data on lead compound

FDA grants priority review to nintedanib NDA for IPF

Taiho Pharmaceutical seeks additional indication approval in Japan for Zosyn

Rifaximin achieves endpoint in phase III trial in IBS with diarrhea

Boehringer Ingelheim files MAAs for tiotropium/olodaterol combination in Europe

Actavis completes Furiex acquisition

Pozen resubmits aspirin/omeprazole NDAs to the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...